These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 30696949)

  • 41. Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
    Nadeem O; Aranha MP; Redd R; Timonian M; Magidson S; Lightbody ED; Alberge JB; Bertamini L; Dutta AK; El-Khoury H; Bustoros M; Laubach JP; Bianchi G; O'Donnell E; Wu T; Tsuji J; Anderson K; Getz G; Trippa L; Richardson PG; Sklavenitis-Pistofidis R; Ghobrial IM
    medRxiv; 2024 Apr; ():. PubMed ID: 38699307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
    Delimpasi S; Dimopoulos MA; Straub J; Symeonidis A; Pour L; Hájek R; Touzeau C; Bhanderi VK; Berdeja JG; Pavlíček P; Matous JV; Robak PJ; Suryanarayan K; Miller A; Villarreal M; Cherepanov D; Srimani JK; Yao H; Labotka R; Orlowski RZ
    Am J Hematol; 2024 Sep; 99(9):1746-1756. PubMed ID: 38856176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
    Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
    J Clin Oncol; 2020 Jun; 38(17):1928-1937. PubMed ID: 32298201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
    Yang Y; Xia ZJ; Zhang WH; Fu CC; Bao L; Chen B; Ding KY; Wang SL; Luo J; Li BZ; Hua LM; Yang W; Zhou X; Wang L; Xu TH; Wang WD; Wu GL; Huang Y; Li J; Liu P
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):628-634. PubMed ID: 34547867
    [No Abstract]   [Full Text] [Related]  

  • 46. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
    Iida S; Izumi T; Komeno T; Terui Y; Chou T; Ikeda T; Berg D; Fukunaga S; Sugiura K; Sasaki M
    Int J Clin Oncol; 2022 Jan; 27(1):224-233. PubMed ID: 34599726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
    Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
    Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
    Dash AB; Zhang J; Shen L; Li B; Berg D; Lin J; Avet-Loiseau H; Bahlis NJ; Moreau P; Richardson PG; Di Bacco A
    Eur J Haematol; 2020 Sep; 105(3):274-285. PubMed ID: 32350909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
    Furlan A; Cea M; Pavan L; Galli M; Clissa C; Mangiacavalli S; Cafro AM; Girlanda S; Patriarca F; Minotto C; Bertoldero G; Barilà G; Pascarella A; Lico A; Paolini R; Rabassi N; Pescosta N; Porrazzo M; De Sabbata G; Pompa A; Bega G; Cavallin S; Guidotti F; Marcatti M; Rupolo M; Belotti A; Gherlinzoni F; Zambello R
    Cancer Med; 2024 Apr; 13(7):e7071. PubMed ID: 38558233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
    Iida S; Izumi T; Aotsuka N; Komeno T; Ishida T; Sunami K; Handa H; Berg D; Kase Y; Soeda J
    Rinsho Ketsueki; 2018; 59(11):2399-2407. PubMed ID: 30531133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma.
    Ohashi Y; Yatabe M; Niijima D; Tani K; Ogawa C; Yachi Y; Kagoo T; Boku S; Ueno H; Yano T; Higai K; Yokoyama A
    In Vivo; 2020; 34(5):2821-2828. PubMed ID: 32871820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
    Liu A; Yu H; Hou R; Zhu Z; Zhuang JL; Bao L; Li Z; Liu L; Hua L; Ma Y; Gao D; Jin A; Suo X; Yang W; Bai Y; Fu R; Zheng D; Chen W
    Cancer Med; 2024 May; 13(9):e7177. PubMed ID: 38686615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
    Szudy-Szczyrek A; Chocholska S; Bachanek-Mitura O; Czabak O; Mlak R; Szczyrek M; Muzyka-Kasietczuk J; Hus M
    Ann Agric Environ Med; 2022 Mar; 29(1):103-109. PubMed ID: 35352912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
    Horigome Y; Iino M; Harazaki Y; Kobayashi T; Handa H; Hiramatsu Y; Kuroi T; Tanimoto K; Matsue K; Abe M; Ishida T; Ito S; Iwasaki H; Kuroda J; Shibayama H; Sunami K; Takamatsu H; Tamura H; Hayashi T; Akagi K; Maeda T; Yoshida T; Mori I; Shinozaki T; Iida S
    Ann Hematol; 2024 Feb; 103(2):475-488. PubMed ID: 37695378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
    Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
    Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
    Di Bacco A; Bahlis NJ; Munshi NC; Avet-Loiseau H; Masszi T; Viterbo L; Pour L; Ganly P; Cavo M; Langer C; Kumar SK; Rajkumar SV; Keats JJ; Berg D; Lin J; Li B; Badola S; Shen L; Zhang J; Esseltine DL; Luptakova K; van de Velde H; Richardson PG; Moreau P
    Eur J Haematol; 2020 Jul; 105(1):35-46. PubMed ID: 32145111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
    Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
    Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.